Rising Biosciences (Rising Biosciences) EV-to-EBIT : (As of Jun. 18, 2024)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Rising Biosciences's Enterprise Value is $0.00 Mil. Rising Biosciences does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Rising Biosciences's EV-to-EBIT at this moment.

The historical rank and industry rank for Rising Biosciences's EV-to-EBIT or its related term are showing as below:

RBII's EV-to-EBIT is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 17.055
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Rising Biosciences's Enterprise Value for the quarter that ended in . 20 was $0.00 Mil. Rising Biosciences does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in . 20. Therefore, GuruFocus does not calculate Rising Biosciences's Earnings Yield (Joel Greenblatt) % at this moment.

Rising Biosciences EV-to-EBIT Historical Data

The historical data trend for Rising Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences EV-to-EBIT Chart

Rising Biosciences Annual Data

Trend

EV-to-EBIT

Rising Biosciences Quarterly Data

EV-to-EBIT

Competitive Comparison of Rising Biosciences's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's EV-to-EBIT falls into.

Rising Biosciences EV-to-EBIT Calculation

Rising Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/
	=

Rising Biosciences (GREY:RBII) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Rising Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: . 20 )	=	EBIT	/	Enterprise Value (Q: . 20 )
	=		/
	=	%

Rising Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » EV-to-EBIT

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.